Results of treatment for male prolactinomas

被引:0
|
作者
Iwai, Y [1 ]
Yamanaka, K [1 ]
Ishiguro, T [1 ]
Morikawa, T [1 ]
Matsuzaka, Y [1 ]
Komiyama, M [1 ]
Yasui, T [1 ]
机构
[1] Osaka City Gen Hosp, Dept Neurosurg, Miyakojima Ku, Osaka 5340021, Japan
来源
NEUROLOGICAL SURGERY | 2002年 / 30卷 / 12期
关键词
prolactinoma; male; bromocriptine; dopamine agonist; pituitary gland;
D O I
暂无
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
We evaluated the results of medical treatment for male prolactinomas. We encountered eight patients with male prolactinomas. The age was 25 to 54 years old (mean 43 years) and the chief clinical symptoms were visual acuity/field defect in three patients, pituitary apoplexy in one patient, disturbance of ejection in one patient, generalized convulsion in one patient, headache in one patient and general fatigue in one patient. The serum prolactin level was 279 to 7,360ng/ml (mean 2,832ng/ml). The tumors in all patients were large with a mean diameter of 34.9mm (range, 21 to 43mm). In only one patient, the operation was performed due to pituitary apoplexy. All the patients were treated by medication, with bromocriptine being used in seven patients and, terguride in one. The follow-up period was 0.8 to 13 years (mean 5.9 years) and, in all patients, the medical treatment was continued. The tumor decreased in size in all patients and the serum prolactin level at the last follow-up observation was 0.5 to 70.5ng/ml (mean 26.9ng/ml). All the neurological symptoms disappeared in the early stage of treatment., As for the complications of medical treatment; in one patient, orthostatic hypotension occurred during the initial administration of bromocriptine and one patient suffered CSF leakage two months after the administration of bromocriptine, so the repair of the sella floor by transsphenoidal surgery was necessary. The medical treatment for male prolactinomas is effective for a long term and should be the primary treatment for the male prolactinomas. In conclusion, patients can maintain a good quality of life for a long time by using dopamine agonists
引用
收藏
页码:1285 / 1292
页数:8
相关论文
共 50 条
  • [31] TREATMENT OF PROLACTINOMAS WITH MEGAVOLTAGE RADIOTHERAPY
    TEASDALE, G
    THOMSON, JA
    MACPHERSON, P
    BRITISH MEDICAL JOURNAL, 1984, 288 (6429): : 1538 - 1539
  • [32] 2012 update in the treatment of prolactinomas
    Maiter, Dominique
    Primeau, Vanessa
    ANNALES D ENDOCRINOLOGIE, 2012, 73 (02) : 90 - 98
  • [33] SURGICAL-TREATMENT OF PROLACTINOMAS
    JEZERNIK, M
    PODBOJ, J
    KLUN, B
    POVHE, B
    KOCIJANCIC, A
    PREZELJ, J
    ZDRAVSTVENI VESTNIK, 1982, 51 (05): : 251 - 253
  • [34] THE USE OF SURGERY FOR THE TREATMENT OF PROLACTINOMAS
    VANTVERLAAT, JW
    ACTA ENDOCRINOLOGICA, 1993, 129 : 34 - 37
  • [35] Challenges and controversies in the treatment of prolactinomas
    Vroonen, Laurent
    Daly, Adrian F.
    Beckers, Albert
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2014, 9 (06) : 593 - 604
  • [36] Surgical treatment of prolactinomas: cons
    Eve Bloomgarden
    Mark E. Molitch
    Endocrine, 2014, 47 : 730 - 733
  • [37] TREATMENT OF PROLACTINOMAS - EFFICACY OF RADIOTHERAPY
    WERDER, KV
    GOTTSMANN, M
    BRENDEL, C
    LANDGRAF, R
    LIEVEN, HV
    RJOSK, HK
    FAHLBUSCH, R
    ACTA ENDOCRINOLOGICA, 1978, 87 : 1 - 1
  • [38] BROMOCRIPTINE TREATMENT OF PROLACTINOMAS - REPLY
    MCGREGOR, AM
    HALL, K
    SCANLON, MF
    HALL, R
    NEW ENGLAND JOURNAL OF MEDICINE, 1979, 300 (24): : 1392 - 1392
  • [39] BROMOCRIPTINE TREATMENT OF PROLACTINOMAS IN PREGNANCY
    NEHMZOW, M
    VENTZ, M
    MENG, W
    ZENTRALBLATT FUR GYNAKOLOGIE, 1985, 107 (14): : 899 - 903
  • [40] Experience in the Treatment of Male Prolactinomas: A Single-Center, 10-Year Retrospective Study
    Ke, Xiaoan
    Chen, Xiaoxue
    Wang, Linjie
    Duan, Lian
    Yang, Hongbo
    Yao, Yong
    Deng, Kan
    Pan, Hui
    Gong, Fengying
    Zhu, Huijuan
    NEUROENDOCRINOLOGY, 2024,